After colocalization and SMR analysis, 6 plasma proteins (FCRL3, SUGP1, TNFAIP3, EHBP1, HAPLN4, and CILP2) have been passed all tests and identified as having potential as therapeutic targets for RA. This evidence concerns the gene HAPLN4 and rheumatoid arthritis.